Abivax SA American Depositary Shares (ABVX)vsNovartis AG ADR (NVS)
ABVX
Abivax SA American Depositary Shares
$106.24
-3.30%
HEALTHCARE · Cap: $8.42B
NVS
Novartis AG ADR
$147.85
+3.44%
HEALTHCARE · Cap: $282.11B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 1237931% more annual revenue ($56.58B vs $4.57M). NVS leads profitability with a 23.9% profit margin vs 0.0%. NVS earns a higher WallStSmart Score of 51/100 (C-).
ABVX
Avoid22
out of 100
Grade: F
NVS
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ABVX.
Margin of Safety
-52.5%
Fair Value
$109.60
Current Price
$147.85
$38.25 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Areas to Watch
Trading at 15.6x book value
0.0% earnings growth
0.0% margin — thin
Weak financial health signals
Expensive relative to growth rate
Grey zone — moderate risk
Revenue declined 0.7%
Earnings declined 9.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : ABVX
ABVX has a balanced fundamental profile.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bear Case : ABVX
The primary concerns for ABVX are Price/Book, EPS Growth, Profit Margin.
Bear Case : NVS
The primary concerns for NVS are PEG Ratio, Altman Z-Score, Revenue Growth.
Key Dynamics to Monitor
ABVX profiles as a value stock while NVS is a declining play — different risk/reward profiles.
NVS carries more volatility with a beta of 0.52 — expect wider price swings.
NVS is growing revenue faster at -0.7% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 22/100), backed by strong 23.9% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Abivax SA American Depositary Shares
HEALTHCARE · BIOTECHNOLOGY · USA
Abivax SA is a clinical-stage biotechnology company dedicated to developing groundbreaking immunotherapies for chronic inflammatory diseases and viral infections, leveraging its lead candidate ABX464, currently undergoing clinical trials for ulcerative colitis and other indications. The firm employs a unique combination of antibody-mediated therapies and proprietary compounds to address significant unmet medical needs, positioning itself favorably within the healthcare landscape. With a promising pipeline and a skilled scientific team committed to innovation, Abivax represents a compelling investment opportunity for institutional stakeholders looking to capitalize on advancements in the immunotherapy sector.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?